Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.